Routine Tandem Transplantation for Patients with Myeloma
Authors: Jayesh Mehta
Journal: Annals of Internal Medicine (2003)

Letters1 July 2003Routine Tandem Transplantation for Patients with MyelomaJayesh Mehta, MDJayesh Mehta, MDNorthwestern University Feinberg School of Medicine; Chicago, IL 60611 (Mehta)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-139-1-200307010-00020-w1 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:As Imrie and colleagues have shown (1), routine tandem transplantation has no place in the treatment of myeloma. Although an earlier French study (2) found a marginal advantage in patients receiving two transplants, this may well be attributable to the conditioning regimen of melphalan and total-body irradiation used for single transplants, which has been shown to be inferior to high-dose melphalan (200 mg/m2) alone (3). Data from the Royal Marsden Hospital (4) show that median overall and event-free survival are similar in patients receiving a single transplant and 200 mg/m2 of melphalan and patients undergoing tandem transplantation ...References1. Imrie K, Esmail R, Meyer RM. The role of high-dose chemotherapy and stem-cell transplantation in patients with multiple myeloma: a practice guideline of the Cancer Care Ontario Practice Guidelines Initiative. Ann Intern Med. 2002;136:619-29. [PMID: 11955031] LinkGoogle Scholar2. Attal M, Harousseau JL, Facon T. Single versus double transplant in myeloma: a randomized trial of the InterGroupe Franais du Mylome (IFM) [Abstract]. Presented at VIIIth International Myeloma Workshop, Banff, Alberta, Canada, 48 May 2001. Page 28 (S15). Google Scholar3. Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F, . Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood. 2002;99:731-5. [PMID: 11806971] MedlineGoogle Scholar4. Sirohi B, Powles R, Mehta J, Kulkarni S, Treleaven J, Horton C, et al. Single-center results of 200 mg/m2 melphalan (HDM200) and autograft (tx) in 451 myeloma (MM) patients: identifying patients with prolonged survival based upon albumin (ALB) and beta2-globulin (B2M) at transplant [Abstract]. Presented at American Society of Clinical Oncology Annual Meeting, Orlando, Florida, 1821 May 2002. Abstract no. 1072. Available at www.asco.org/ac/1,1003,_12-002095,00.asp. Google Scholar5. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, . Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93:55-65. [PMID: 9864146] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Northwestern University Feinberg School of Medicine; Chicago, IL 60611 (Mehta) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoThe Role of High-Dose Chemotherapy and Stem-Cell Transplantation in Patients with Multiple Myeloma: A Practice Guideline of the Cancer Care Ontario Practice Guidelines Initiative Kevin Imrie , Rosmin Esmail , Ralph M. Meyer , and Metrics 1 July 2003Volume 139, Issue 1Page: W-54KeywordsMyelomaSalvage antiretroviral therapyTransplantation ePublished: 1 July 2003 Issue Published: 1 July 2003 Copyright & PermissionsCopyright © 2003 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...